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Abstract: Age-related macular degeneration (AMD) is a leading cause of blindness in the developed
world. The retinal pigment epithelium (RPE) is a critical site of pathology in AMD. Oxidative stress
plays a key role in the development of AMD. We generated a chimeric high-density lipoprotein
(HDL), mimetic peptide named HM-10/10, with anti-oxidant properties and investigated its potential
for the treatment of retinal disease using cell culture and animal models of RPE and photoreceptor
(PR) degeneration. Treatment with HM-10/10 peptide prevented human fetal RPE cell death caused
by tert-Butyl hydroperoxide (tBH)-induced oxidative stress and sodium iodate (NaIO3), which causes
RPE atrophy and is a model of geographic atrophy in mice. We also show that HM-10/10 peptide
ameliorated photoreceptor cell death and significantly improved retinal function in a mouse model of
N-methyl-N-nitrosourea (MNU)-induced PR degeneration. Our results demonstrate that HM-10/10
protects RPE and retina from oxidant injury and can serve as a potential therapeutic agent for the
treatment of retinal degeneration.
Keywords: retinal pigment epithelium (RPE); sodium iodate; geographic atrophy; retinitis pigmentosa;
apoptosis; HDL-mimetic peptide; OCT; retinal function
1. Introduction
Age-related macular degeneration (AMD) is characterized by progressive degeneration of the
macular region of the retina resulting in loss of central vision. It causes damage to the central part of
the retina, resulting in the loss of the light-sensitive tissue at the back of the eye. AMD is the leading
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cause of irreversible blindness in people aged 50 or older in the developed world and there is no
complete cure for AMD [1]. The key to reducing the AMD-related vision loss is to be able to initiate
therapies that could halt or slow down the progression of AMD.
High density lipoprotein (HDL) is an important mediator of lipid homeostasis. HDL and
HDL associated molecules provide a number of protective functions including anti-inflammatory,
antioxidant, anti-microbial, and innate immunity in multiple cell types and animal models [2]. HDL
mimetic peptides have shown efficacy in a number of animal models of disease and demonstrate
properties that make them attractive as potential therapeutic agents [3–7]. We developed a novel
chimeric high density lipoprotein; mimetic peptide named HM-10/10. The arginine-rich cationic
domain of human apoE {([141–150] hApoE) L-R-K-L-R-K-R-L-L-R}, was added to an apoJ mimetic,
named G * peptide {L-V-G-R-Q-L-E-E-F-L, corresponding to amino acids 113 to 122 in apoJ ([113,122]
apoJ)}, to form HM-10/10 peptide containing 20 amino acids with the sequence of L-R-K-L-R-K-R-L-L-
R-L-V-G-R-Q-L-E-E-F-L.
Our aim in this study was to evaluate whether HM-10/10 peptide is beneficial in protecting retinal
pigment epithelium (RPE) and photoreceptors from oxidant induced cell death under in vitro and
in vivo conditions. We found that HM-10/10 peptide prevents oxidative stress induced in human
fetal RPE (hfRPE) cells. Further, we show that HM-10/10 peptide protects RPE and retinal for sodium
iodate (NaIO3)-induced geographic atrophy as well as in a retinitis pigmentosa model of photoreceptor
degeneration by N-methyl-N-nitrosourea (MNU). Our studies indicate that HM-10/10 could be pursued
as a novel therapeutic agent for treating retinal disease.
2. Results
2.1. HM-10/10 Peptide Significantly Inhibited Cell Death from tBH Treatment of hfRPE Cells
We examined the effect of HM-10/10 peptide on apoptosis in cell culture models. We first conducted
dose response studies for HM-10/10 in hfRPE cells (Supplemental Figure S1) and based on the results
we used HM-10/10 at 10 µg/mL concentration in all the hfRPE cell culture experiments. hfRPE cells
were cultured overnight in 0.5% serum containing DMEM medium and were either treated with
HM-10/10 alone at 10 µg/mL or with 200 µM tert-Butyl hydroperoxide (tBH) [8,9] alone or with a
combination of tBH and HM-10/10 for 24 h. Apoptosis was analyzed by TUNEL staining and as
shown in Figure 1, tBH caused a significant increase in TUNEL positive cells in hfRPE and HM-10/10
significantly inhibited cell death of hfRPE cells, and also significantly inhibited apoptotic cell death
induced by tBH (p = 0.002).
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Figure 1. HM-10/10 peptide inhibits peroxide-induced apoptosis in human fetal retinal pigment 
epithelium (hfRPE) cells. hfRPE cells were incubated with HM-10/10 at 10 μg/mL alone or 200 μM 
tert-Butyl hydroperoxide (tBH) alone or the treated with a combination of tBH and HM-10/10 for 24h 
as described under Materials and Methods. Apoptosis was analyzed and quantified by TUNEL 
staining (lower panel). Representative images are shown in the upper panel. White scale bar = 100 
μm. Blue: DAPI nuclear staining; Red: TUNEL positive apoptotic nuclei staining. Asterisk indicates p 
< 0.008 with the Beonferroni correcition. 
2.2. HM-10/10 Peptide Significantly Reduced Apoptotic Cell Death from NaIO3 Treatment of hfRPE Cells  
We next examined the effect of HM-10/10 peptide on apoptosis in NaIO3-induced hfRPE cell 
cultures. We performed a time course of NaIO3-induced cell death (Supplemental Figure S2) and 
chose 24 h time point for subsequent experiments. As shown in Figure 2, treatment of hfRPE cells 
with either 200 μg/mL or 500 μg/mL of NaIO3 resulted in increased TUNEL-positive apoptotic cells; 
the induction of cell death was much higher with 500 ug/mL NaIO3 as compared to 200 μg/mL dose 
(Figure 2). Co-treatment with HM-10/10 peptide (10 μg/mL) at either concentration of NaIO3 
significantly reduced apoptotic cell death (p = 0.003 or p < 0.0001). 
Figure 1. HM-10/10 peptide inhibits peroxide-induced apoptosis in human fetal retinal pigment
epithelium (hfRPE) cells. hfRPE cells were incubated with HM-10/10 at 10 µg/mL alone or 200 µM
tert-Butyl hydroperoxide (tBH) alone or the treated with a combination of tBH and HM-10/10 for 24 h as
described under Materials and Methods. Apoptosis was nalyzed and quantified by TUNEL staining
(lower panel). Rep esentative images are shown in the upper panel. White scale bar = 100 µm. Blue:
DAPI nuclear stai ing; ed: TUNEL positive apoptotic nuclei staining. Asterisk ndi t s p < 0.0 8
with the Beonferroni correcit on.
2.2. HM-10/10 Peptide Significantly Reduced Apoptotic Cell Death from NaIO3 Treatment of hfRPE Cells
We next examined the effect of HM-10/10 peptide on apoptosis in NaIO3-induced hfRPE cell
cultures. We performed a time course of NaIO3-induced cell death (Supplemental Figure S2) and chose
24 h time point for subsequent experiments. As shown in Figure 2, treatment of hfRPE cells with either
200 µg/mL or 500 µg/mL of NaIO3 resulted in increased TUNEL-positive apoptotic cells; the induction
of cell death was uch higher with 500 ug/mL NaIO3 as compared to 200 µg/mL dose (Figure 2).
Co-treatment with HM-10/10 peptide (10 µg/mL) at either concentration of NaIO3 significantly reduced
apoptotic cell death (p = 0.003 or p < 0.0001).
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Figure 2. HM-10/10 peptide mitigates sodium iodate (NaIO3)-induced increase in apoptosis of hfRPE 
cells. hfRPE cells were incubated with HM-10/10 peptide at 10 μg/mL, or NaIO3 at either 200 μg/mL 
or 500 ug/mL, or treated with NaIO3 and HM-10/10 together, for 24 h as described under Materials 
and Methods. Apoptosis was analyzed and quantified by TUNEL staining (lower panel). 
Representative images showing TUNEL-positive apoptotic nuclei (red) and DAPI (blue) in all groups 
(upper panel). White scale bar = 100 μm. Asterisk indicates p < 0.0036 with the Bonferroni correction. 
2.3. HM-10/10 Peptide Protected hfRPE Cells from Oxidative Stress by Inhibiting Activation of Caspase-3/7 
To further examine the apoptotic mechanism, we analyzed the activation of Caspase-3/7 in 
hfRPE cells using both the IncuCyte live imaging assay and Western Blot analysis (Figure 3). We used 
the IncuCyte® Caspase-3/7 Green Apoptosis Assay to determine the effect of HM-10/10 peptide on 
apoptosis in hfRPE cells. The green object counts of dead cells were increased when the cells were 
treated with either tBH or NaIO3 alone, but were significantly reduced when co-treated with HM-
10/10 (p < 0.05) (Figure 3A). Western blot analysis showed cleaved Caspase-3 activation at 24 h was 
elevated in hfRPE cells treated with 200 μM tBH or NaIO3 alone, whereas co-treatment with HM-
10/10 inhibited activation of Caspase-3 (Figure 3B). 
Figure 2. HM-10/10 peptide mitigates sodium iodate (NaIO3)-induced increase in apoptosis of hfRPE
cells. hfRPE cells were incubated with HM-10/10 peptide at 10 µg/mL, or NaIO3 at either 200 µg/mL or
500 ug/mL, or treated with NaIO3 and HM-10/10 together, for 24 h as described under Materials and
Methods. Apoptosis was analyzed and quantified by TUNEL staining (lower panel). Representative
images showing TUNEL-positive apoptotic nuclei (red) and DAPI (blue) in all groups (upper panel).
White scale bar = 100 µm. Asterisk indicates p < 0.0036 with the Bonferroni correction.
2.3. HM-10/10 Peptide Protected hfRPE Cells from Oxidative Stress by Inhibiting Activation of Caspase-3/7
To further examine the apoptotic mechanism, we analyzed the activation of Caspase-3/7 in hfRPE
cells using both the IncuCyte live imaging assay and Western Blot analysis (Figure 3). We used the
IncuCyte® Caspase-3/7 Green Apoptosis Assay to determine the effect of HM-10/10 peptide on apoptosis
in hfRPE cells. The green object counts of dead cells were increased when the cells were treated
with either tBH or NaIO3 alone, but were significantly reduced when co-treated ith HM-10/10 (p <
0.05) (Figure 3A). Western blot analysis showed cleaved Caspase-3 activation at 24 h was elevated in
hfRPE cells treated with 200 µM tBH or NaIO3 alone, whereas co-treatment with HM-10/10 inhibited
activation of Caspase-3 (Figure 3B).
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Figure 3. HM-10/10 inhibits the activation of Caspase-3/7 in hfRPE cells. hfRPE cells were incubated with 
HM-10/10 peptide at 10 μg/mL, tBH at 200 μM, or NaIO3 at either 200 μg/mL or 500 μg/mL alone, or 
treated with tBH and HM-10/10 together, or NaIO3 and HM-10/10 together, for 24 h as described under 
Materials and Methods. (A) The IncuCyte® Caspase-3/7 Green Apoptosis Assay was used to determine 
the inhibitory effect of HM-10/10 peptide on cell proliferation of hfRPE cells. Representative images of the 
green object counts of dead cells are shown in the right panel. Automated real-time experiment by 
IncyCyte Zoom measured as green object count for all cells stained green with SYTOX Green. 
Magnification bar equals 400 μm. (B) The activation of Caspase-3 in hfRPE cells was determined by 
Western blot analysis. Asterisk indicates p < 0.05 with the Bonferroni correction. 
2.4. Optimizing NaIO3 Doses in Vivo. 
We next sought to determine the protective effects of HM-10/10 peptide on retinal damage in 
vivo. HM-10/10 and other HDL mimetic peptides have been tested orally in C57BL6/J mice 
(unpublished data). NaIO3 treatment has been successfully used by others and us to study RPE 
degeneration in geographic atrophy in animal models [10,11]. Since previous dose response studies 
in NaIO3-induced RPE atrophy was performed in 129S6/SvEv and TAC mice [10,11], we first 
conducted a NaIO3 dose-response experiment to test the efficacy of HM-10/10 in C57BL6/J male mice. 
These experiments were conducted using doses of NaIO3 at 15, 20, and 35 mg/kg body weight (BW) 
administrated via tail vein injections to C57BL6/J male mice. Mice were fed a standard chow diet and 
after one week the extent of retinal damage was determined from optical coherence tomography 
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Figure 3. HM-10/10 inhibits the activation of Casp se-3/7 in hfRPE cells. hfRPE cells were incubated
with HM-10/10 peptide at 10 µg/ L, tB at 200 µ , or aI at either 200 µg/ L or 500 µg/ L alone,
or treated with tBH and HM-10/10 together, or NaIO3 and HM-10/10 together, for 24 h as described
under Materials and Methods. (A) The IncuCyte® Caspase-3/7 Green Apoptosis Assay was used to
determine the inhibitory effect of HM-10/10 peptide on cell proliferation of hfRPE cells. Representative
images of the g een object counts of d ad c lls are shown in the right panel. Automat d real-ti e
experiment by IncyCyte Zoom measured as green object count for all cells stained green with SYTOX
Green. Magnification bar equals 400 µm. (B) The activation of Caspase-3 in hfRPE cells was determined
by Western blot analysis. Asterisk indicates p < 0.05 with the Bonferroni correction.
2.4. Optimizing NaIO3 Doses In Vivo
We next sought to determine the protective effects of HM-10/10 peptide on retinal damage in vivo.
HM-10/10 and other HDL mimetic peptides have been tested orally in C57BL6/J mice (unpublished
data). NaIO3 treatment has been successfully used by others and us to study RPE degeneration in
geographic atrophy in animal models [10,11]. Since previous dose response studies in NaIO3-induced
RPE atrophy was performed in 129S6/SvEv and TAC mice [10,11], we first conducted a NaIO3
dose-response experiment to test the efficacy of HM-10/10 in C57BL6/J male mice. These experiments
were conducted using doses of NaIO3 at 15, 20, and 35 mg/kg body weight (BW) administrated via
tail vein injections to C57BL6/J male mice. Mice were fed a standard chow diet and after one week
the extent of retinal damage was determined from optical coherence tomography (OCT) images by
measuring overall retinal thickness (see supplemental Figure S3 in the Supplementary Material for
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comprehensive image analysis). Retinal thickness decreased significantly with increasing dose of
NaIO3. Based on this finding, we chose a NaIO3 dose of 20 mg/kg BW in our subsequent experiments.
2.5. In Vivo Assessment of Retinal Structure Using Optical Coherence Tomography
C57BL6/J male mice were given an intravenous injection of NaIO3 at 20 mg/kg BW or the vehicle
PBS via tail vein. Mice were fed either a standard chow diet or a chow diet containing HM-10/10 at
100 mg/kg BW. OCT images were taken every week following the start of the treatment up to three
weeks. Representative OCT and en face infrared fundus images for all the treatments are shown in
Figure 4A. The mice receiving NaIO3 alone demonstrated a disruption in retinal structure, particularly
in the outer retinal layers and RPE, with overall thinning of the retina. H&E staining established
that the outer retinal layers are disorganized with discrete areas of debris in the RPE and outer retina
consistent with outer retinal cell death. As a measure of damage to the retina, overall thickness
measures were made from the OCTs using on-screen calipers positioned at discrete locations on either
side of the optic nerve head. These thickness measures, shown in Figure 4B, demonstrate a thinning of
the retina even after one-week exposure to NaIO3. The mice given NaIO3 plus the peptide in their
chow also demonstrated an overall thinning of the retina. However, the addition of the peptide to
the chow mitigated the toxic effect of NaIO3 and overall thinning was not as severe as in the group
receiving NaIO3 alone (Figure 4B). Histological analysis of the retina after three weeks of treatment
demonstrated findings consistent with in vivo OCT analysis. NaIO3 treatment caused a significant
decrease in the number of nuclei in the outer nuclear layer (ONL) compared with the control mice.
There was no significant difference in ganglion cell layer (GCL) or inner nuclear layer (INL) cell
nuclei, but a significant difference in the ONL across all conditions. Importantly, HM-10/10 in the diet
significantly improved the structure of the ONL compared to the group without the peptide, but did
not restore ONL thickness to control values (Figure 4C). The representative histopathology images
are shown in Figure 4C. Immunohistochemistry (IHC) staining of cleaved Caspase-3 of retinal tissue
sections after three weeks of treatment showed lesser intensity of staining for Caspase-3 in the RPE
layer (NaIO3 + HM-10/10) fed with HM-10/10 at 100 mg/kg BW compared with mice that received
NaIO3 alone (Figure 4D).
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Figure 4. HM-10/10 treatment prevents degenerative changes in retina induced by intravenous NaIO3. 
Eye in vivo optical coherence tomography (OCT) images and the fundus photographs were taken 
after one, two, and three weeks of NaIO3 treatment as described under Materials and Methods. The 
mice were sacrificed at the end of three weeks. Retinal sections were scanned. (A) Degenerative 
changes shown by representative OCT and fundus images from Control, NaIO3, and NaIO3 + HM-
10/10 groups of mice. Horizontal and vertical extents of fundus images are 1.4 × 1.4 mm, respectively. 
(B) Retinal thickness measurements from all three weeks of the study represented as bar graphs. (C) 
The numbers of nuclei were counted from each layer as described under Materials and Methods. The 
representative histopathology images showing decreased number of nuclei with NaIO3 treatment as 
compared to control and partial recovery in the number of nuclei with HM-10/10 treatment to that of 
control. Bar equals 50 μm. GCL: Ganglion cell layer; ONL: Outer nuclear layer; INL: Inner nuclear 
layer. (D) Immunohistochemistry staining of cleaved Caspase-3 (red) of retinal tissue sections. 
Bonferroni method was used to adjust the p < 0.0016 for multiple pairwise comparisons. 
2.6. HM-10/10 Caused Protection of Photoreceptor Degeneration and Improvement of Visual Function in 
MNU Mouse Model of Retinal Degeneration. 
The MNU + HM-10/10 treatment protocol consisted of both pre- and post-treatments. The retinal 
thickness of H&E stained sections were quantified to determine HM-10/10 induced protective effects 
on photoreceptors. The number of nuclei in ONL of MNU group and MNU + HM-10/10 group was 
reduced after MNU administration when compared with the control group. However, the mean 
number of nuclei in ONL from MNU + HM-10/10 group was significantly increased compared with 
MNU group (p < 0.0001, Figure 5A). The overall retina for MNU+HM-10/10 group was significantly 
thicker than MNU group (p = 0.0014, Figure 5A) as expected. Furthermore, the TUNEL assay was 
Figure 4. HM-10/10 treatment prevents degenerative changes in retina induced by intravenous NaIO3.
Eye in vivo optical coherence tomography (OCT) images and the fundus photographs were taken after
one, two, and three weeks of NaIO3 treatment as described under Materials and Methods. The mice
were sacrificed at the end of three weeks. Retinal sections were scanned. (A) Degenerative changes
shown by representative OCT and fundus images from Control, NaIO3, and NaIO3 + HM-10/10 groups
of mice. Horizontal and vertical extents of fundus images are 1.4 × 1.4 mm, respectively. (B) Retinal
thickness measurements from all three weeks of the study represented as bar graphs. (C) The numbers
of nuclei were counted from each layer as described under Materials and Methods. The representative
histopathology images showing decreased number of nuclei with NaIO3 treatment as compared to
control and partial recovery in the number of nuclei with HM-10/10 treatment to that of control. Bar
equals 50 µm. GCL: Ganglion cell layer; ONL: Outer nuclear layer; INL: Inner nuclear layer. (D)
Immunohistochemistry staining of cleaved Caspase-3 (red) of retinal tissue sections. Bonferroni method
was used to adjust the p < 0.0016 for multiple pairwise comparisons.
2.6. HM-10/10 Caused Protection of Photoreceptor Degeneration and Improvement of Visual Function in MNU
Mouse odel of Retinal Degeneration
The MNU + HM-10/10 treatment protocol consisted of both pre- and post-treatments. The retinal
thickness of H&E stained sections were quantified to determine HM-10/10 induced protective effects
on photoreceptors. The number of nuclei in ONL of MNU group and MNU + HM-10/10 group was
reduced after MNU administration when compared with the control group. However, the mean
number of nuclei in ONL from MNU + HM-10/10 group was significantly increased compared with
MNU group (p < 0.0001, Figure 5A). The overall retina for MNU+HM-10/10 group was significantly
Int. J. Mol. Sci. 2019, 20, 4807 8 of 17
thicker than MNU group (p = 0.0014, Figure 5A) as expected. Furthermore, the TUNEL assay was
performed to quantify the apoptotic activity in photoreceptors. No apparent TUNEL-positivity was
detected in the retinas of the normal control group, while many TUNEL-positive cells were found in the
retinas of MNU group. Most of the TUNEL-positive cells were concentrated in the ONL, suggesting that
MNU toxicity induced extensive photoreceptor apoptosis in mice retinas. TUNEL-positive cells were
also detected in the retinas of the MNU+HM-10/10 group. However, the number of TUNEL-positive
cells in MNU+HM-10/10 group was significantly less than that in MNU group (p < 0.00001; Figure 5B),
suggesting that HM-10/10 treatment could alleviate the MNU induced photoreceptor apoptosis.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 9 of 17 
 
Figure 5. HM-10/10 protective effects on photoreceptors and on visual function in MNU mouse 
model. C57BL6/J male mice were injected with MNU via intraperitoneal injection and received pre- 
or post-treatment of HM-10/10 in chow as described under Materials and Methods. After the 
treatment, retinal damage was analyzed and electroretinography (ERG) retinal function tests were 
assessed. (A) The numbers of nuclei were counted from each layer and retinal thickness was measured 
as described under Materials and Methods. (B) TUNEL assay was performed to quantify the apoptotic 
activity in retinas. (C) Representative OCT cross-sectional image overlapped at the optic nerve head of 
the retina depicting the architectural trauma of the outer retina (upper panel) and overlapped bar 
graphs comparing the overall retinal thickness measurements to the composite three cell layers (lower 
panel). Horizontal extent of OCT cross-sections is 1.4 mm. (D) Representative waveforms of the 
brightest stimulus from each group under scotopic (0.2 cd·s/m2) and photopic (6.0 cd·s/m2) conditions 
(upper two panels). Averages and SEM of the saturated retinal response amplitudes by group (lower 
panel). (E) Representative I-R functions for each group according to flash strength. Asterisk indicates 
p < 0.0016 with the Bonferroni correction. 
3. Discussion 
HM-10/10 is a novel member of a class of HDL-mimetic peptides. HM-10/10 is constructed by 
utilizing specific sequences from apoE and apoJ proteins, both of which have been used previously 
in other HDL-mimetic iterations [12,13]. The chimeric peptide AEM-28 [14] has an 18 amino acid 
apoA-I mimetic peptide attached to C-terminal end of the apoE part of HM-10/10. AEM-28 has been 
shown to regulate dyslipidemia and inflammation in animal models [14]. The apoJ part of HM-10/10 
is a G * peptide that has been shown to confer anti-oxidant and anti-inflammatory properties in 
animal models [15]. We designed HM-10/10 to confer both the lipid clearing of AEM-28 and the anti-
inflammatory properties of G * peptide. 
ApoA-I and HDL-mimetic peptides have been investigated in many animal models of disease. 
ApoA-I mimetic peptide 4F has been tested in two human studies [16–18] by oral administration and 
by intravenous (IV) or subcutaneous (SQ) administration [19]. The two oral studies [16,17] reported 
efficacy with doses of ≥ 3.3 mg/kg BW; lower doses were ineffective. At the time that the IV and SQ 
studies were designed, it was thought that these peptides acted in plasma, so the key success factor 
would be plasma peptide levels. Since these peptides are very expensive to produce, and the IV and 
Figure 5. HM-10/10 protective effects on photoreceptors and on visual function in MNU mouse
model. C57BL6/J male mice were injected with MNU via intraperitoneal injection and received pre- or
post-treatment of HM-10/10 in chow as described under Materials and Methods. After the treatment,
retinal damage was analyzed and electroretinography (ERG) retinal function tests were assessed. (A)
The numbers of nuclei were counted from each layer and retinal thickness was measured as described
under Materials and Methods. (B) TUNEL assay was performed to quantify the apoptotic activity
in retinas. (C) Representative OCT cross-sectional image overlapped at the optic nerve head of the
retina depicting the architectural trauma of the outer retina (upper panel) and overlapped bar graphs
comparing the overall retinal thickness measurements to the composite three cell layers (lower panel).
Horizontal extent of OCT cross-sections is 1.4 mm. (D) Representative waveforms of the brightest
stimulus from each group under scotopic (0.2 cd·s/m2) and photopic (6.0 cd·s/m2) conditions (upper
two panels). Averag s and SEM of the aturated retinal response amplitudes by group (lower panel).
(E) Representative I-R functions for ach group according to flash s rength Asterisk indicates p <
0.0016 with the Bonferroni correction.
Representative in vivo OCT images are shown in Figure 5C for the three treatment groups. Both
the MNU and the MNU+HM-10/10 mice demonstrated structural disruption in the outer retina,
particularly in the outer nuclear layer and its corresponding outer segments (Figure 5C upper panel).
To quantify these changes, global thickness measures were obtained for the RPE, the outer retina
(from RPE to inner nuclear layer), the nerve fiber layer, and total retinal thickness, as described above.
Consistent with the NaIO3 study groups, the overall retina was thinner in the MNU treatment groups
compared to the control with a mitigating effect of the HM10-10 peptide. Further analysis revealed
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that the composite measure responsible for the overall thinning (and rescue) effect was the outer retina.
Significant differences across the three groups were observed only for the outer retina—the thicknesses
of the inner retina and the RPE were not significantly different across the three groups (Figure 5C lower
panel, p = 0.001). Thus, the in vivo OCT analysis is consistent with the TUNEL assay suggesting that
MNU toxicity induced massive retinal photoreceptor apoptosis in mice which was mitigated by the
peptide treatment.
Retinal function was evaluated with electroretinography (ERG). Figure 5D shows representative
ERG responses to single intensity flashes under scotopic and photopic conditions. Figure 5E shows
representative intensity-response functions for each treatment group under dark-adapted conditions.
The MNU treatment groups clearly show the weakest responses with better responses for the MNU
+ peptide group. The I-R functions were fitted with the Naka-Ruston equation to estimate Vmax,
the saturated retinal response. The experimental groups that received an injection of MNU alone or
received MNU+HM-10/10 peptide treatment in their chow showed significantly lower amplitude
responses under scotopic and photopic conditions than that for the control group (p = 0.0009, p = 0.005,
respectively) (Figure 5D). However, the responses from those that received MNU plus HM-10/10
peptide treatment in their chow were significantly better than those that received MNU alone as
demonstrated by the average Vmax (± 1 se) across the three treatment conditions (p < 0.0001) (Figure 5D).
Thus, the toxic effects of MNU were mitigated and the functional consequences were less severe
following the peptide treatment.
3. Discussion
HM-10/10 is a novel member of a class of HDL-mimetic peptides. HM-10/10 is constructed by
utilizing specific sequences from apoE and apoJ proteins, both of which have been used previously
in other HDL-mimetic iterations [12,13]. The chimeric peptide AEM-28 [14] has an 18 amino acid
apoA-I mimetic peptide attached to C-terminal end of the apoE part of HM-10/10. AEM-28 has been
shown to regulate dyslipidemia and inflammation in animal models [14]. The apoJ part of HM-10/10
is a G * peptide that has been shown to confer anti-oxidant and anti-inflammatory properties in
animal models [15]. We designed HM-10/10 to confer both the lipid clearing of AEM-28 and the
anti-inflammatory properties of G * peptide.
ApoA-I and HDL-mimetic peptides have been investigated in many animal models of disease.
ApoA-I mimetic peptide 4F has been tested in two human studies [16–18] by oral administration and
by intravenous (IV) or subcutaneous (SQ) administration [19]. The two oral studies [16,17] reported
efficacy with doses of ≥3.3 mg/kg BW; lower doses were ineffective. At the time that the IV and SQ
studies were designed, it was thought that these peptides acted in plasma, so the key success factor
would be plasma peptide levels. Since these peptides are very expensive to produce, and the IV and
SQ routes yield much higher plasma levels, these studies used lower doses. Consequently, in the IV
and SQ studies [19], the maximum dose tested was 1.43 mg/kg BW; a dose that was ineffective in the
two oral studies [16,17]. As expected, IV or SQ administration achieved dramatically higher plasma
peptide levels, but surprisingly efficacy was not achieved [19]. These seemingly conflicting results
led us to complete a series of studies that quite unexpectedly revealed that the peptides work in the
intestine rather than in the plasma [20–27]. Therefore, we decided to use HM-10/10 peptide via an
oral route.
Murine NaIO3 model is widely used as a model of RPE degeneration that occurs in geographic
atrophy. It results in reproducible patch retinal degeneration and can be studied in a wide variety of
wild type and genetic knock out strains. The sequence of events leading to retinal damage after NaIO3
will depend on the source of NaIO3, methods of administration, animals (type, strain, and age), and
time points analyzed after injection [10,11]. High doses (50–100 mg/kg) lead to rapid complete ablation
of the outer nuclear and RPE layer [28,29] while lower doses (15–35 mg/kg/kg) of NaIO3 are associated
with decreased visual function as well as focal RPE loss and minimal outer retinal damage [11,30,31].
We and others have shown that the RPE damage results from increased ROS levels both in vitro and
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in vivo [10,31–33]. Several oxidative stress regulatory pathways such as Akt phosphorylation, PTEN,
Nrf2, and mTOR have been shown to be involved [32,34,35]. The mechanism of cell death in RPE with
NaIO3 is through apoptotic pathways although necroptosis has also been reported [36]. Investigations
on the participation of specific pathways linked to the protective action of HM-10/10 in the retina will
be of value and are being actively pursued in our laboratory.
To our knowledge, this is the first report on the role of a HDL-mimetic peptide in retinal protection.
The beneficial effects of HM-10/10 peptide in protecting RPE/retina may arise from a combination of
mechanisms for the neutralization of the oxy-radicals generated by the oxidant of NaIO3. Mitochondria
are the prime source for the production of reactive oxygen species [37]. An effect of HM-10/10 may
likely involve improvement of cellular, particularly mitochondrial function in stressed RPE/retina.
For example, HM-10/10 peptide could upregulate GSH and enzymes of GSH biosynthesis as well as
detoxify superoxide enzymes such as MnSOD. Our previous work has shown the expression and
localization of GSH metabolizing enzymes and redoxin family of proteins in RPE cells and their
regulation by oxidative stress [38,39]. Further, the mechanism of protection from caspase activation and
ensuing apoptotic cell death by HM-10/10 peptide may be mediated by mitochondrial GSH (mGSH).
mGSH plays a significant role in cellular defense against pro-oxidants, the depletion of mGSH affects
cell viability, either by predisposing cells to apoptosis or by modulating mitochondrial membrane
potential and subsequent activation of caspases through regulation of redox pathways [40]. We have
reported that short chain (20–24-mer) bioactive peptides offer neuroprotection by selective upregulation
of mitochondrial GSH [39,41,42]. Moreover, we have previously shown that D-4F, an apoA-I mimetic
peptide, inhibits proliferation, and tumorigenicity of epithelial ovarian cancer cells by upregulating
the antioxidant enzyme MnSOD [6].
The effect of oxidative stress in causing tissue inflammation is well established. The involvement
of inflammation in the pathogenesis of AMD is well known and inflammasomal activation is implicated
in AMD mediated by various risk factors [43,44]. NLRP3-mediated RPE death has been intensively
debated due to the complicated involvement caspase proteins in AMD pathogenesis. Recently Mao
et al. [45] found that mesenchymal stem cells protected NaIO3 triggered RPE death by deactivating
NFkappaB mediated NLRP3 inflammasome and mitochondrial integrity. Our present data show
that the activation of caspase 3/7 by NaIO3 in hfRPE is inhibited by HM-10/10 thereby preventing
apoptotic cell death. Diverse AMD stressors may jointly influence and determine the ultimate cell fate
via different pathways and thus it is conceivable that in addition to caspase 3, caspase 1 and NLRP3
inflammasome are activated with NaIO3 and HM-10/10 may inhibit these pathways.
Whether HM-10/10 peptide could mitigate cell death in vivo was assessed using OCT in the
NaIO3 mouse model. Mice given an intravenous injection of NaIO3 demonstrated a significant
thinning of the retina with heterogeneous disruption of the outer retina and RPE by OCT analysis, as
previously reported [10,11]. However, those for which the HM-10/10 peptide was added to their chow
showed significantly less disorganization of the outer retina, and less overall retinal thinning by OCT
and immunohistochemistry, but did not completely rescue the normal phenotype (see supplemental
Figure S1).
In addition to determining the beneficial effect of HM-10/10 peptide in dry AMD, we also
investigated its effect in an experimental model of retinitis pigmentosa. MNU is known to induce
concentration-dependent retinal degeneration mostly in the outer nuclear layer [46,47]. Retinitis
pigmentosa is a blinding human disease that is characterized by the progressive loss of photoreceptor
cells. Therefore, MNU-treated animals might serve as a model to study disease-associated features [47,48].
Both caspase dependent and caspase independent pathways for photoreceptor (PR) degeneration have
been reported [47,48]. In addition, Endoplasmic Reticulum (ER) stress has been identified as another
important cause of MNU-induced PR damage [49].
We found that MNU treatment gave evidence for selective loss of PR cells in the ONL as determined
by apoptosis using TUNEL assays (Figure 5). Further, the consequences on retinal function were
assessed by ERG. Treatment with MNU reduced retinal function to near non-detectable levels except
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at the brightest flash intensities, consistent with severe disruption of the outer- and middle-retina.
When HM-10/10 peptide was added to their chow, retinal function was better than those mice that
did not receive the peptide (Figure 5). Overall, in vivo assessments of retinal structure and function
demonstrated improvements in HM-101/10 treated retinas, but did not restore the normal phenotype.
Finally, it is well known that the damage to mitochondria with oxidative, environmental,
and genetic factors can lead to damage to mitochondrial DNA. Evidence implicates mitochondrial
damage in the AMD disease process [37,50]. A potential link between mitochondrial dysfunction
due to increased mitochondrial lesions and AMD has been reported [51,52]. Thus protecting DNA
via therapeutics targeted to mitochondria in early in AMD could ameliorate or stop the progress to
vision loss. Our results demonstrate that HM-10/10 peptide protects RPE and retina from oxidative
damage in experimental models of geographic atrophy and retinitis pigmentosa suggests that it may
be a promising therapeutic candidate in the prevention of AMD.
4. Materials and Methods
4.1. Mice
Six-week-old C57BL6/J male mice were purchased from The Jackson Laboratory (The Jackson
Laboratory, Bar Harbor, ME, USA). The Animal Research Committee at the University of California
Los Angeles approved the mouse experimental protocols. All procedures used in this study were
conducted in accordance with National Institutes of Health guidelines and the Association for Research
in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic Vision Research. UCLA
approved animal protocol 2004-161-33A was used. The title of the protocol is “The role of ApoAI
and its peptides on inhibiting age-related pro-inflammatory diseases including cancer and retinal
degeneration”. The approval period is valid till 19 May 2020.
4.2. HM-10/10 Peptide
HDL mimetic, HM-10/10 peptide (L-R-K-L-R-K-R-L-L-R-L-V-G-R-Q-L-E-E-F-L) was synthesized
from all L-amino acids. The peptide had >98% purity, as determined by high-performance liquid
chromatography (HPLC) and mass spectrometry (MS). The peptide was dissolved in H2O for cell
culture and the administration in a chow diet for in vivo studies. The peptide was mixed into standard
mouse chow (Ralston Purina) using techniques as described previously [19]. Each evening, the frozen
diet was provided. The mice consumed all of the diet by next morning.
4.3. hfRPE Cell Culture Experiments
Early passage [2–4] primary cultured human fetal retinal pigment epithelial cells were cultured in
10% FBS DMEM medium [53]. Media was changed to 0.5% FBS DMEM the day before the treatment.
Cells were treated with 200 uM tert-Butyl hydroperoxide (Sigma, St. Louis, MO, USA) or NaIO3
(200 µg/mL or 500 µg/mL) (Sigma, St. Louis, MO, USA) for 12 h or 24 h with or without the co-treatment
of HM-10/10 at 10 µg/mL. hfRPE cells were cultured in glass bottom microwell dishes (MatTek, Ashland,
MA, USA) and fixed in 4% paraformaldehyde solution and rinsed with PBS. Apoptotic cell death was
measured using TUNEL assay according to the manufacturer′s instructions (Roche, Indianapolis, IN,
USA). The number of TUNEL-positive cells was counted from eight different areas of each treatment
under a fluorescent microscope and the average number of apoptotic cells was recorded. By using the
IncuCyte live-cell analysis system (Essen BioScience, Ann Arbor, MI, USA), hfRPE cells were cultured
in 96-well plates and imaged every hour up to 24 h after treatment to measure cell health and viability
in real time. The data was analyzed by using the IncuCyte S3 software (Essen BioScience, Ann Arbor,
MI, USA). Experiments were performed in quadruplicate; data were expressed as the mean of the
quadruplicate determinations (mean ± SD).
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4.4. Western Blot Analysis
Total cell proteins were collected at the end of indicated treatments in cell lysis buffer containing
0.1 M NaCl, 5 mM EDTA, 50 mM sodium orthovanadate, 1% Triton X-100, and protease inhibitor tablet
in 50 mM Tris buffer (pH 7.5). 50 µg of total proteins were separated by SDS-PAGE and transferred
onto nitrocellulose membrane, and followed by incubation with primary antibody at 4 ◦C in 5% skim
milk and 0.1% Tween-20. Anti-cleaved Caspase-3 antibody (Cell Signaling, Danvers, MA, USA) was
used at the dilution of 1:1000, and anti-GAPDH polyclonal secondary antibody was used at 1:5000.
4.5. Immunohistochemistry (IHC) Staining
Frozen retinal tissue sections were fixed with cold acetone at −20 ◦C for 10 min; and then blocked
with 10% normal serum and 4% BSA prepared in PBS for three hours; then incubated with 1:500
rabbit polyclonal anti-cleaved Caspase-3 antibody (Cell Signaling, Danvers, MA, USA) overnight at
4 ◦C. Following washes, the sections were incubated with biotinylated secondary antibody (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA) for one hour at room temperature, followed by
incubation with Vectastain ABC Elite reagents (Vector Laboratories. Burlingame, CA, USA).
4.6. TUNEL Assay
The TUNEL (terminal deoxyuridine triphosphate nick-end labeling) assay was performed on
frozen retinal sections to analyze the apoptotic status of the retinas. The In Situ Cell Death Detection
Kit (Roche Diagnostics, Indianapolis, IN, USA) was used according to the manufacturer′s protocol.
The TUNEL sections were counterstained with DAPI, mounted on slides, and then visualized with
fluorescence microscopy (Leica Camera Inc., Allendale, NJ, USA). The apoptotic cells/mm2 on ONL
was calculated ([number of TUNEL-positive nuclei]/[mm2 Area of ONL]).
4.7. Spectral Domain Optical Coherence Tomography (SD-OCT) and Fundus Images
Ultra-high resolution spectral domain optical coherence tomography (SD-OCT) imaging was
performed on both eyes for all groups, at one, two and three weeks post treatment or at the end of
experiments, using a Bioptigen SD-OCT system (Research Triangle Park, Durham, NC, USA). A series
of 100 b-scans were collected, stacked and aligned spatially to form a registered three-dimensional
rendering of retinal volume. A high resolution horizontal b-scan centered on the optic nerve head was
captured by averaging and spatially aligning 20 individual b-scans along the same horizontal axis.
On screen calipers were placed at three equidistant locations on either side of the optic nerve head
spanning the entire OCT image. At each location the total retinal thickness, defined as the distance
(in µm) from the retinal pigment epithelium to the inner limiting membrane, was measured. The six
measurements were averaged to provide a composite retinal thickness measure for each eye. Fundus
images were obtained using the Micron II retinal imaging microscope (Phoenix Research Laboratories,
Inc., CA, USA). For both OCT and fundus imaging, mice were anesthetized with an intraperitoneal (IP)
injection of normal saline solution containing ketamine (15 mg/g body weight) and xylazine (7 mg/g
body weight) and pupil dilation was accomplished by adding a drop of 1% atropine sulfate. The mouse
was placed on a movable platform so that the eye could be aligned with the axis of the imaging device.
4.8. Electroretinography
Following overnight dark-adaptation, mice were anesthetized with an intraperitoneal injection
of saline containing ketamine (15 mg/kg body weight) and xylazine (7 mg/kg body weight). ERGs
were recorded from the corneal surface after pupil dilation (1% atropine sulfate) using a gold loop
corneal electrode together with a mouth reference and tail ground electrode. A drop of methylcellulose
(2.5%) on the corneal surface was used to ensure electrical contact and to maintain corneal integrity.
Body temperature was maintained at 38 ◦C with a heated water pad. All stimuli were presented in a
large integrating sphere coated with highly reflective white matte paint (Eastman Kodak Corporation,
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Rochester, NY, USA). Responses were amplified (Grass CP511 AC amplifier, × 10,000) and digitized
using an I/O board (National Instruments, Austin, TX, USA) in a personal computer. Signal processing
was performed with custom software LabWindows/CVI (National Instruments, Austin, TX, USA).
For each stimulus condition, responses were computer-averaged with up to 50 records averaged for
the weakest signals. A signal rejection window was adjusted on-line to eliminate artifacts. All stimuli
were presented at 1 Hz except for the brightest flashes where the presentation rate was slowed to
0.2 Hz. The intensity-response functions were analyzed to extract Vmax, the maximum saturated
b-wave amplitude.
4.9. Animal Models
Two mouse models were used in this study: NaIO3 model of RPE atrophy and MNU model of
photoreceptor degeneration.
4.9.1. NaIO3 Model
At the beginning of in vivo studies, we performed a NaIO3 dose-response experiment with the
C57BL/6J mice to identify the optimal doses to test the efficacy of our peptide. C57BL6/J male mice
were treated with NaIO3 doses ranging from 15 mg/kg to 35 mg/kg BW administrated via tail vein
injections. Mice were fed a standard chow diet and after one week the extent of retinal damage was
determined from OCT images by measuring overall retinal thickness.
Based on the dose-response data, we chose a NaIO3 concentration of 20 mg/kg for our subsequent
experiments. Eighteen six-week-old C57BL6/J male mice were divided into three treatment groups
consisting of six mice per group. The groups were: (1) control group (Control): Mice with tail vein
injection of PBS (vehicle), fed with standard chow diet; (2) NaIO3-treated mice (NaIO3): Mice with
tail vein injection of NaIO3 at 20 mg/kg BW [10], fed with standard chow diet; (3) NaIO3-treated mice
with peptide (NaIO3 + HM-10/10): Mice received NaIO3 at 20 mg/kg via tail vein, fed with HM-10/10
peptide at 100 mg/kg body weight added to chow. Diet treatments were started on the same day the
mice received the tail vein injections of PBS or NaIO3. At the end of each week, SD-OCT and fundus
images were taken and analyzed. After three weeks of treatment, eyes were enucleated, and frozen
sections of retinal tissue were used for histology. Retinal sections were scanned, the nuclei were
counted from each layer and retinal thickness was quantified by Aperial Scan Scope (Leica Biosystems,
Buffalo Grove, IL) using Aperio software as described previously [54].
4.9.2. MNU Model
Retinal degeneration in MNU administered mice occurred within seven days with a dose of
60 mg/kg [55,56] which has been used in several therapeutic trials [11,12].
MNU solution at 5 mg/mL was prepared by dissolving reagent in physiological saline containing
0.05% acetic acid. The mice received a single intraperitoneal injection of MNU (Chem Service Inc., West
Chester, PA, USA) at 60 mg/kg BW. Twelve mice were randomly assigned to three groups: (1) control
group (Control): Mice received intraperitoneal (ip) injection of vehicle (physiological saline containing
0.05% acetic acid) and a standard chow; (2) MNU group (MNU): Mice received ip injection of MNU at
60 mg/kg BW and a standard chow; (3) MNU + HM-10/10 group (MNU + HM-10/10): Mice received ip
injection of MNU at 60 mg/kg BW and fed with a diet containing HM-10/10 at 100 mg/kg BW added to
chow. The mice received the regular chow or a chow containing HM-10/10 three days before MNU
administration. On day five after MNU, SD-OCT images were taken and ERG function tests were
analyzed. Eyes were enucleated, and frozen sections of retinal tissue were used for histology and
TUNEL assay. Retinal sections were scanned, the numbers of nuclei were counted from each layer and
retinal thickness was quantified.
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4.10. Statistical Analyses
The data are shown as means ± SD for each group. Statistical analyses were performed by
the Student′s t–test, one-way or two-way ANOVA by Graph-Pad Prism 3.01. Difference between
groups was established with Bonferroni′s post-hoc test. A p-value of less than 0.05 was considered
statistically significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/19/
4807/s1.
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Abbreviations
AMD Age-related macular degeneration
BW Body weight
ERG Electroretinography
HDL High density lipoprotein
RPE Retinal pigment epithelium
MNU N-methyl-N-nitrosourea
NaIO3 Sodium iodate
PR Photoreceptor
SD-OCT Spectral domain optical coherence tomography
tBH+ tert-Butyl hydroperoxide
TUNEL Terminal deoxyuridine triphosphate nick-end labeling
References
1. Pennington, K.L.; DeAngelis, M.M. Epidemiology of age-related macular degeneration (AMD): Associations
with cardiovascular disease phenotypes and lipid factors. Eye Vis. 2016, 3, 34. [CrossRef] [PubMed]
2. Navab, M.; Reddy, S.T.; Van Lenten, B.J.; Anantharamaiah, G.M.; Fogelman, A.M. The role of dysfunctional
HDL in atherosclerosis. J. Lipid Res. 2009, 50, S145–S149. [CrossRef] [PubMed]
3. Su, F.; Kozak, K.R.; Imaizumi, S.; Gao, F.; Amneus, M.W.; Grijalva, V.; Ng, C.; Wagner, A.; Hough, G.;
Farias-Eisner, G.; et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development
in a mouse model of ovarian cancer. Proc. Natl. Acad. Sci. USA 2010, 107, 19997–20002. [CrossRef] [PubMed]
4. Su, F.; Grijalva, V.; Navab, K.; Ganapathy, E.; Meriwether, D.; Imaizumi, S.; Navab, M.; Fogelman, A.M.;
Reddy, S.T.; Farias-Eisner, R. HDL mimetics inhibit tumor development in both induced and spontaneous
mouse models of colon cancer. Mol. Cancer Ther. 2012, 11, 1311–1319. [CrossRef] [PubMed]
5. Gao, F.; Vasquez, S.X.; Su, F.; Roberts, S.; Shah, N.; Grijalva, V.; Imaizumi, S.; Chattopadhyay, A.; Ganapathy, E.;
Meriwether, D.; et al. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing
VEGF/basic FGF signaling pathways. Integr. Biol. 2011, 3, 479–489. [CrossRef] [PubMed]
6. Ganapathy, E.; Su, F.; Meriwether, D.; Devarajan, A.; Grijalva, V.; Gao, F.; Chattopadhyay, A.;
Anantharamaiah, G.M.; Navab, M.; Fogelman, A.M.; et al. D-4F, an apoA-I mimetic peptide, inhibits
proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme
MnSOD. Int. J. Cancer 2012, 130, 1071–1081. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 4807 15 of 17
7. Gao, F.; Chattopadhyay, A.; Navab, M.; Grijalva, V.; Su, F.; Fogelman, A.M.; Reddy, S.T.; Farias-Eisner, R.
Apolipoprotein A-I mimetic peptides inhibit expression and activity of hypoxia-inducible factor-1α in human
ovarian cancer cell lines and a mouse ovarian cancer model. J. Pharmacol. Exp. Ther. 2012, 342, 255–262.
[CrossRef] [PubMed]
8. Sreekumar, P.G.; Ishikawa, K.; Spee, C.; Mehta, H.H.; Wan, J.; Yen, K.; Cohen, P.; Kannan, R.; Hinton, D.R.
The mitochondrial-derived peptide humanin protects RPE cells from oxidative stress, senescence, and
mitochondrial dysfunction. Invest. Ophthalmol. Vis. Sci. 2016, 57, 1238–1253. [CrossRef] [PubMed]
9. Kannan, R.; Zhang, N.; Sreekumar, P.G.; Spee, C.K.; Rodriguez, A.; Barron, E.; Hinton, D.R. Stimulation
of apical and basolateral VEGF-A and VEGF-C secretion by oxidative stress in polarized retinal pigment
epithelial cells. Mol. Vis. 2006, 12, 1649–1659. [PubMed]
10. Zhou, P.; Kannan, R.; Spee, C.; Sreekumar, P.G.; Dou, G.; Hinton, D.R. Protection of retina by αB-crystallin in
sodium iodate induced retinal degeneration. PLoS ONE 2014, 5, e98275. [CrossRef] [PubMed]
11. Kannan, R.; Hinton, D.R. Sodium ioate induced retinal degeneratin: New insights from an old model.
Neural Regen. Res. 2014, 9, 2044–2045. [PubMed]
12. Navab, M.; Ruchala, P.; Waring, A.J.; Lehrer, R.I.; Hama, S.; Hough, G.; Palgunachari, M.N.;
Anantharamaiah, G.M.; Fogelman, A.M. A novel method for oral delivery of apolipoprotein mimetic
peptides synthesized from all L-amino acids. J. Lipid Res. 2009, 50, 1538–1547. [CrossRef] [PubMed]
13. Navab, M.; Anantharamaiah, G.M.; Reddy, S.T.; Van Lenten, B.J.; Datta, G.; Garber, D.; Fogelman, A.M.
Potential clinical utility of high-density lipoprotein-mimetic peptides. Curr. Opin Lipidol. 2006, 17, 440–444.
[CrossRef] [PubMed]
14. White, C.R.; Garber, D.W.; Anantharamaiah, G.M. Anti-inflammatory and cholesterol-reducing properties of
apolipoprotein mimetics: A review. J. Lipid Res. 2014, 55, 2007–2021. [CrossRef] [PubMed]
15. Navab, M.; Anantharamaiah, G.M.; Reddy, S.T.; Van Lenten, B.J.; Wagner, A.C.; Hama, S.; Hough, G.;
Bachini, E.; Garber, D.W.; Mishra, V.K.; et al. An oral apoJ peptide renders HDL antiinflammatory in mice
and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler. Thromb.
Vasc. Biol. 2005, 25, 1932–1937. [CrossRef] [PubMed]
16. Bloedon, L.T.; Dunbar, R.; Duffy, D.; Pinell-Salles, P.; Norris, R.; DeGroot, B.J.; Movva, R.; Navab, M.;
Fogelman, A.M.; Rader, D.J. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic
peptide D-4F in high-risk cardiovascular patients. J. Lipid Res. 2008, 49, 1344–1352. [CrossRef] [PubMed]
17. Dunbar, R.L.; Movva, R.; Bloedon, L.T.; Duffy, D.; Norris, R.B.; Navab, M.; Fogelman, A.M.; Rader, D.J. Oral
apolipoprotein A-I mimetic D-4F lowers HDL-inflammatory index in high-risk patients: A first-in-human
multiple dose, randomized controlled trial. Clin. Transl. Sci. 2017, 10, 455–469. [CrossRef]
18. Watson, C.E.; Weissbach, N.; Kjems, L.; Ayalasomayajula, S.; Zhang, Y.; Chang, I.; Navab, M.; Hama, S.;
Hough, G.; Reddy, S.T.; et al. Treatment of patients with cardiovascular disease with L-4F, an apoA-I mimetic,
did not improve select biomarkers of HDL function. J. Lipid Res. 2011, 52, 361–373. [CrossRef]
19. Navab, M.; Reddy, S.T.; Anantharamaiah, G.M.; Imaizumi, S.; Hough, G.; Hama, S.; Fogelman, A.M. Intestine
may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or
orally. J. Lipid Res. 2011, 52, 1200–1210. [CrossRef]
20. Navab, M.; Reddy, S.T.; Anantharamaiah, G.M.; Hough, G.; Buga, G.M.; Danciger, J.; Fogelman, A.M.
D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated
with decreased inflammation in low-density lipoprotein receptor-null mice. J. Lipid Res. 2012, 53, 437–445.
[CrossRef]
21. Chattopadhyay, A.; Navab, M.; Hough, G.; Gao, F.; Meriwether, D.; Grijalva, V.; Springstead, J.R.;
Palgnachari, M.N.; Namiri-Kalantari, R.; Su, F.; et al. A novel approach to oral apoA-I mimetic therapy.
J. Lipid Res. 2013, 54, 995–1010. [CrossRef]
22. Navab, M.; Hough, G.; Buga, G.M.; Su, F.; Wagner, A.C.; Meriwether, D.; Chattopadhyay, A.; Gao, F.;
Grijalva, V.; Danciger, J.S.; et al. Transgenic 6F tomatoes act on the small intestine to prevent systemic
inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid.
J. Lipid Res. 2013, 54, 3403–3418. [CrossRef]
23. Navab, M.; Chattopadhyay, A.; Hough, G.; Meriwether, D.; Fogelman, S.I.; Wagner, A.C.; Grijalva, V.; Su, F.;
Anantharamaiah, G.M.; Hwang, L.H.; et al. Source and role of intestinally derived lysophosphatidic acid in
dyslipidemia and atherosclerosis. J. Lipid Res. 2015, 56, 871–887. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 4807 16 of 17
24. Chattopadhyay, A.; Grijalva, V.; Hough, G.; Su, F.; Mukherjee, P.; Farias-Eisner, R.; Anantharamaiah, G.M.;
Faull, K.F.; Hwang, L.H.; Navab, M.; et al. Efficacy of tomato concentrates in mouse models of dyslipidemia
and cancer. Pharmacol. Res. Perspect. 2015, 3, e00154. [CrossRef]
25. Chattopadhyay, A.; Navab, M.; Hough, G.; Grijalva, V.; Mukherjee, P.; Fogelman, H.R.; Hwang, L.H.;
Faull, K.F.; Lusis, A.J.; Reddy, S.T.; et al. Tg6F ameliorates the increase in oxidized phospholipids in the
jejunum of mice fed unsaturated LysoPC or WD. J. Lipid Res. 2016, 57, 832–847. [CrossRef]
26. Mukherjee, P.; Hough, G.; Chattopadhyay, A.; Navab, M.; Fogelman, H.R.; Meriwether, D.; Williams, K.;
Bensinger, S.; Moller, T.; Faull, K.F.; et al. Transgenic tomatoes expressing the 6F peptide and ezetimibe
prevent diet-induced increases of IFN-β and cholesterol 25-hydroxylase in jejunum. J. Lipid Res. 2017, 58,
1636–1647. [CrossRef]
27. Chattopadhyay, A.; Yang, X.; Mukherjee, P.; Sulaiman, D.; Fogelman, H.R.; Grijalva, V.; Dubinett, S.;
Wasler, T.C.; Paul, M.K.; Salehi-Rad, R.; et al. Treating the intestine with oral apoA-I mimetic Tg6F reduces
tumor burden in mouse models of metastatic lung cancer. Sci. Rep. 2018, 8, 9032. [CrossRef]
28. Kiuchi, K.; Yoshizawa, K.; Shikata, N.; Moriguchi, K.; Tsubura, A. Morphologic characteristics of retinal
degeneration induced by sodium iodate in mice. Curr. Eye Res. 2002, 25, 373–379. [CrossRef]
29. Enzmann, V.; Row, B.W.; Yamauchi, Y.; Kheirandish, L.; Gozal, D.; Kaplan, H.J.; McCall, M.A. Behavioral and
anatomical abnormalities in a sodium iodate-induced model of retinal pigment epithelium degeneration.
Exp. Eye Res. 2006, 82, 441–448. [CrossRef]
30. Franco, L.M.; Zulliger, R.; Wolf-Schnurrbusch, U.E.; Katagiri, Y.; Kaplan, H.J.; Wolf, S.; Enzmann, V.
Decreased visual function after patchy loss of retinal pigment epithelium induced by low-dose sodium
iodate. Invest. Ophthalmol. Vis. Sci. 2009, 50, 4004–4010. [CrossRef]
31. Machalin´ska, A.; Lejkowska, R.; Duchnik, M.; Kawa, M.; Rogin´ska, D.; Wiszniewska, B.; Machalin´ski, B.
Dose-dependent retinal changes following sodium iodate administration: Application of spectral-domain
optical coherence tomography for monitoring of retinal injury and endogenous regeneration. Curr. Eye Res.
2014, 39, 1033–1041. [CrossRef]
32. Sachdeva, M.M.; Cano, M.; Handa, J.T. Nrf2 signaling is impaired in the aging RPE given an oxidative insult.
Exp. Eye Res. 2014, 119, 111–114. [CrossRef]
33. Qin, S.; Lu, Y.; Rodrigues, G.A. Resveratrol protects RPE cells from sodium iodate by modulating PPARα
and PPARδ. Exp. Eye Res. 2014, 118, 100–108. [CrossRef]
34. Zhao, S.G.; Li, Q.; Liu, Z.X.; Wang, J.J.; Wang, X.X.; Qin, M.; Wen, Q.S. Curcumin attenuates insulin resistance
in hepatocytes by inducing Nrf2 nuclear translocation. Hepatogastroenterology 2011, 58, 2106–2111. [CrossRef]
35. Kim, H.L.; Nam, S.M.; Chang, B.J.; Nahm, S.S.; Lee, J.H. Ultrastructural Changes and Expression of PCNA and
RPE65 in Sodium Iodate-Induced Acute Retinal Pigment Epithelium Degeneration Model. Neurochem. Res.
2018, 43, 1010–1019. [CrossRef]
36. Hanus, J.; Anderson, C.; Sarraf, D.; Ma, J.; Wang, S. Retinal pigment epithelial cell necroptosis in response to
sodium iodate. Cell Death Discov. 2016, 2, 16054. [CrossRef]
37. Jarrett, S.G.; Lin, H.; Godley, B.F.; Boulton, M.E. Mitochondrial DNA damage and its potential role in retinal
degeneration. Prog. Retin. Eye Res. 2008, 27, 596–607. [CrossRef]
38. Sreekumar, P.G.; Ding, Y.; Ryan, S.J.; Kannan, R.; Hinton, D.R. Regulation of thioredoxin by ceramide in
retinal pigment epithelial cells. Exp. Eye Res. 2009, 88, 410–417. [CrossRef]
39. Sreekumar, P.G.; Spee, C.; Ryan, S.J.; Cole, S.P.; Kannan, R.; Hinton, D.R. Mechanism of RPE cell death in
α-crystallin deficient mice: A novel and critical role for MRP1-mediated GSH efflux. PLoS ONE 2012, 7,
e33420. [CrossRef]
40. Marí, M.; Morales, A.; Colell, A.; García-Ruiz, C.; Kaplowitz, N.; Fernández-Checa, J.C. Mitochondrial
glutathione: Features, regulation and role in disease. Biochim. Biophys. Acta 2013, 1830, 3317–3328. [CrossRef]
41. Dou, G.; Sreekumar, P.G.; Spee, C.; He, S.; Ryan, S.J.; Kannan, R.; Hinton, D.R. Deficiency of αB crystallin
augments ER stress-induced apoptosis by enhancing mitochondrial dysfunction. Free Radic. Biol. Med. 2012,
53, 1111–1122. [CrossRef]
42. Matsunaga, D.; Sreekumar, P.G.; Ishikawa, K.; Terasaki, H.; Barron, E.; Cohen, P.; Kannan, R.; Hinton, D.R.
Humanin Protects RPE Cells from Endoplasmic Reticulum Stress-Induced Apoptosis by Upregulation of
Mitochondrial Glutathione. PLoS ONE 2016, 11, e0165150. [CrossRef]
43. Ambati, J.; Fowler, B.J. Mechanisms of age-related macular degeneration. Neuron 2012, 75, 26–39. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 4807 17 of 17
44. Tarallo, V.; Hirano, Y.; Gelfand, B.D.; Dridi, S.; Kerur, N.; Kim, Y.; Cho, W.G.; Kaneko, H.; Fowler, B.J.;
Bogdanovich, S. DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3
inflammasome and MyD88. Cell 2012, 149, 847–859. [CrossRef]
45. Mao, X.; Pan, T.; Shen, H.; Xi, H.; Yuan, S.; Liu, Q. The rescue effect of mesenchymal stem cell on sodium
iodate-induced retinal pigment epithelial cell death through deactivation of NF-κB-mediated NLRP3
inflammasome. Biomed. Pharmacother. 2018, 103, 517–523. [CrossRef]
46. Tsubura, A.; Yoshizawa, K.; Kuwata, M.; Uehara, N. Animal models for retinitis pigmentosa induced by
MNU; disease progression, mechanisms and therapeutic trials. Histol. Histopathol. 2010, 25, 933–944.
47. Zulliger, R.; Lecaudé, S.; Eigeldinger-Berthou, S.; Wolf-Schnurrbusch, U.E.; Enzmann, V. Caspase-3-
independent photoreceptor degeneration by N-methyl-N-nitrosourea (MNU) induces morphological and
functional changes in the mouse retina. Graefes. Arch. Clin. Exp. Ophthalmol. 2011, 249, 859–869. [CrossRef]
48. Yoshizawa, K.; Nambu, H.; Yang, J.; Oishi, Y.; Senzaki, H.; Shikata, N.; Miki, H.; Tsubura, A. Mechanisms of
photoreceptor cell apoptosis induced by N-methyl-N-nitrosourea in Sprague-Dawley rats. Lab. Invest. 1999,
79, 1359–1367.
49. Reisenhofer, M.; Balmer, J.; Zulliger, L.R.; Enzmann, V. Multiple programmed cell death pathways are involved
in N-methyl-N-nitrosourea-induced photoreceptor degeneration. Graefes. Arch. Clin. Exp. Ophthalmol. 2015,
253, 721–731. [CrossRef]
50. Hyttinen, J.M.T.; Błasiak, J.; Niittykoski, M.; Kinnunen, K.; Kauppinen, A.; Salminen, A.; Kaarniranta, K.
DNA damage response and autophagy in the degeneration of retinal pigment epithelial cells-Implications
for age-related macular degeneration (AMD). Ageing Res. Rev. 2017, 36, 64–77. [CrossRef]
51. Karunadharma, P.P.; Nordgaard, C.L.; Olsen, T.W.; Ferrington, D.A. Mitochondrial DNA damage as a
potential mechanism for age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2010, 51, 5470–5479.
[CrossRef] [PubMed]
52. Terluk, M.R.; Kapphahn, R.J.; Soukup, L.M.; Gong, H.; Gallardo, C.; Montezuma, S.R.; Ferrington, D.A.
Investigating mitochondria as a target for treating age-related macular degeneration. J. Neurosci. 2015, 35,
7304–7311. [CrossRef] [PubMed]
53. Sonoda, S.; Spee, C.; Barron, E.; Ryan, S.J.; Kannan, R.; Hinton, D.R. A protocol for the culture and
differentiation of highly polarized human retinal pigment epithelial cells. Nat. Protoc. 2009, 4, 662–673.
[CrossRef] [PubMed]
54. Wang, W.; Sreekuma, P.G.; Valluripalli, V.; Shi, P.; Wang, J.; Lin, Y.A.; Cui, H.; Kannan, R.; Hinton, D.R.;
MacKay, J.A. Protein polymer nanoparticles engineered as chaperones protect against apoptosis in human
retinal pigment epithelial cells. J. Control. Release 2014, 19, 4–14. [CrossRef] [PubMed]
55. Tao, Y.; Chen, T.; Fang, W.; Peng, G.; Wang, L.; Qin, L.; Liu, B.; Fei Huang, Y. The temporal topography of the
N-Methyl-N-nitrosourea induced photoreceptor degeneration in mouse retina. Sci. Rep. 2015, 21, 18612.
[CrossRef] [PubMed]
56. Gao, Y.; Deng, X.G.; Sun, Q.N.; Zhong, Z.Q. Ganoderma spore lipid inhibits N-methyl-N-nitrosourea-induced
retinal photoreceptor apoptosis in vivo. Exp. Eye Res. 2010, 90, 397–404. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
